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Abstract: Neural inhibition plays a key role in determining the specific computational tasks of
different brain circuitries. This functional “braking” activity is provided by inhibitory interneurons
that use different neurochemicals for signaling. One of these substances, somatostatin, is found in
several neural networks, raising questions about the significance of its widespread occurrence and
usage. Here, we address this issue by analyzing the somatostatinergic system in two regions of the
central nervous system: the retina and the hippocampus. By comparing the available information
on these structures, we identify common motifs in the action of somatostatin that may explain its
involvement in such diverse circuitries. The emerging concept is that somatostatin-based signaling,
through conserved molecular and cellular mechanisms, allows neural networks to operate correctly.
Keywords: somatostatin; retina; hippocampus; ion channels; neurotransmitter release; neuromodulation;
information flow; network activity
1. Introduction
Over 40 years after its discovery as hypothalamic peptide inhibiting growth hormone release [1],
somatostatin—also known as somatotropin release-inhibiting factor (SRIF)—has been demonstrated to
exist in several tissues and to mediate a variety of actions [2]. Somatostatin is widely distributed in
the mammalian brain, and somatostatinergic interneurons are recognized as important modulators
of neuronal activity [3–10]. The widespread occurrence of somatostatin-based signaling in different
neural networks suggests that there might be general and shared mechanisms underlying somatostatin
action. To test this hypothesis, in this review, we analyze the properties of the somatostatinergic system
in two model networks: the retina and the hippocampus. These nervous structures deal with different
and highly specialized computational tasks. Nonetheless, we show that somatostatin acts through
common molecular and cellular mechanisms to control information flow across the neuronal circuitries.
Moreover, the available data suggest that somatostatinergic systems play key roles in assuring network
stability so that neurons can operate correctly.
2. An Overview of Retinal and Hippocampal Circuitries
The organization of both retinal and hippocampal circuitries in terms of connectivity and
neurotransmission are well known, and here, we summarize their main features in order to better
understand the mechanisms of somatostatin action described later. Readers may refer to excellent
published reviews for more detailed information (e.g., retina: [11–14]; hippocampus: [15–18]).
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2.1. Retina
In 1893, Ramón y Cajal considered the retina to be “a true nervous center, a peripheral extension
of the central nervous system” and stated that “a study of the retina would shed light on the general
problem of the connection and mechanism of action of nervous cells” [19]. Since then, the retina has
been used extensively as a model of the central nervous system (CNS) for three main reasons [20]:
during embryogenesis, it derives from the diencephalon, that is, the retina is part of the CNS; due its
location, it is readily accessible for experimental studies; it displays an ordered, layered structure with
five basic types of neurons interconnected in a well-defined circuitry (e.g., [21,22]). Retinal neurons
include (Figure 1) photoreceptors (the light sensitive cells: rods and cones), bipolar cells, and ganglion
cells (the output neurons), which represent the principal neurons, and horizontal and amacrine cells,
which constitute the inhibitory interneurons. These cells are organized into clearly distinct layers,
three of which house nerve cell bodies (outer nuclear layer—ONL; inner nuclear layer—INL; ganglion
cell layer—GCL), and the other two contain synaptic contacts (outer plexiform layer—OPL; inner
plexiform layer—IPL) (Figure 1a). The ONL contains cell bodies of rods and cones; the INL contains
cell bodies of bipolar, horizontal, and amacrine cells; and the GCL contains cell bodies of RGCs and
“displaced” amacrine cells. In the OPL, photoreceptors make synaptic contacts with vertically running
bipolar cells and with transversally oriented horizontal cells (Figure 1b). The second synaptic area, IPL,
works simultaneously as a relay point between bipolar cells and ganglion cells, and as a station for
information processing, which is mainly carried out by amacrine cells (Figure 1b). The basic circuitry
within the retina directs the flow of visual information along the pathway, as follows (Figure 1b):
photoreceptor → bipolar cell → ganglion cell (vertical information flow). Two horizontal pathways
modulate this flow (Figure 1b): one provided by horizontal cells in the outer retina, the other formed by
amacrine cells in the inner retina (lateral information flow) [12,23]. Photoreceptors, bipolar cells, and
horizontal cells are nonspiking neurons, although they possess a variety of voltage-gated ion channels
(see Section 4.1). It is worth noting, however, that some cone bipolar cells may express voltage-gated
sodium channels (NaV), which seem to be localized in the soma and dendrites [24–27]. It is believed
that these channels may boost subthreshold depolarizing potentials and therefore facilitate electrotonic
spread to synaptic terminals [28], or they may signal dark to light transitions [29]. On the contrary,
amacrine cells and ganglion cells do generate action potentials.
Retinal chemical synapses play key roles in both vertical and lateral information flow [30].
Glutamate is the excitatory neurotransmitter responsible for the vertical flow of visual signals [31,32].
Glutamate acts on post-synaptic neurons in OPL and IPL through ionotropic (AMPA, kainate, NMDA
receptors) or metabotropic glutamate receptors [31,33–35]. Lateral information flow is mediated
by inhibitory neurotransmitters, such as GABA and glycine, and used by numerous horizontal
and amacrine cells to modulate synaptic transmission in the retinal vertical pathway [12,23,32,34].
In particular, GABA is found in horizontal cells and wide-field amacrine cells, whereas glycine is
expressed by narrow-field amacrine cells [12,36,37]. As output neurons, ganglion cells integrate
excitatory signals from bipolar cells and inhibitory signals from amacrine cells in the IPL before
sending visual information to the thalamus. Although glutamate, GABA, and glycine are the main
substances that mediate fast point-to-point communication, additional neurotransmitters, including
several neuropeptides, are also present in the retina [30,32]. Neuropeptides co-localize with fast-acting
neurotransmitters, adding higher complexity to the signaling mechanism, because they typically
induce responses with a slower onset and of longer duration [38–41].
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Figure 1. Retinal circuitry: (a) Scheme of the eye and sectional view of the layered retina structure. 
Only the three main classes of principal neurons—photoreceptors (green), bipolar cells (light blue), 
and ganglion cells (red)—are shown. RPE, retinal pigment epithelium; ONL, outer nuclear layer; 
OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell 
layer. (b) Schematic drawing of the information flow in retina. Cone and rod photoreceptors send 
signals to bipolar cells, which, in turn, affect the activity of ganglion cells. The axons of ganglion cells 
form the optic nerve. Horizontal cells (gray) and amacrine cells (purple) modulate signal transfer 
across synaptic stations (OPL and IPL). The arrows indicate the vertical and lateral information 
flows. 
2.2. Hippocampus 
The hippocampus, located inside brain temporal lobe, has become a model circuit for 
neuroscientists since the pioneering work on long-term potentiation (LTP) by Bliss and Lømo in 1973 
[42]. The hippocampus plays a key role in learning and memory, and receives highly processed 
sensory information through the entorhinal cortex (EC), which is the gateway to hippocampal 
circuitry [17,18]. The hippocampus contains both principal neurons (granule cells and pyramidal 
cells) and several types of interneurons. The regular organization of principal neurons produces a 
relatively simple layered structure with main synaptic stations in three subfields: the dentate gyrus 
(DG), cornu ammonis 3 (CA3), and cornu ammonis 1 (CA1) [15,17,43] (Figure 2a). Indeed, the 
cellular architecture of transverse hippocampal slice is described as an excitatory tri-synaptic circuit. 
Axons from EC neurons make up the perforant pathway (PP) and terminate on the dendrites of DG 
granule cells. The axons of these cells (mossy fibers) make synapses on the dendrites of CA3 
pyramidal neurons. The latter send their axons (Schaffer collaterals) to the CA1 region and make 
synapses on CA1 pyramidal neurons, the main output neurons projecting to other brain structures, 
such as the subiculum. Thus, the hippocampal circuitry directs information flow along the pathway 
(Figure 2a): DG granule cells  CA3 pyramidal neurons CA1 pyramidal neurons. Across CA3 and 
CA1 subfields, the cell bodies of pyramidal neurons are found in the stratum pyramidale (s.p.), and 
they bear apical (orthogonal) and basal dendritic arborizations (Figure 2b). The apical dendrites 
have a large shaft extending through the stratum radiatum (s.r.) up to the stratum 
lacunosum-moleculare (s.l.m.). Basal dendrites, on the contrary, arborize into the stratum oriens 
(s.o.). It is worth noting that the hippocampal unidirectional mainstream of information flow (Figure 
2a) resembles the vertical communication circuit in the retina (Figure 1). In addition to the main 
tri-synaptic circuit, several local interneuron loops regulate the activity of principal neurons [44,45]. 
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2.2. Hippocampus
The hip ocampus, located inside brain temporal lobe, has become a model circuit for
neuroscientists since the pioneering work on long-term potentiation (LTP) by Bliss and Lømo in
1973 [42]. The hippocampus plays a key role in learning and memory, and receives highly processed
sensory information through the entorhinal cortex (EC), which is the gateway to hippocampal
circuitry [17,18]. The hippocampus contains both principal neurons (granule cells and pyramidal
cells) and several types of interneurons. The regular organization of principal neurons produces a
relatively simple layered structure with main synaptic stations in three subfields: the dentate gyrus
(DG), cornu ammonis 3 (CA3), and cornu ammonis 1 (CA1) [15,17,43] (Figure 2a). Indeed, the cellular
architecture of transverse hippocampal slice is described as an excitatory tri-synaptic circuit. Axons
from EC neurons make up the perforant pathway (PP) and terminate on the dendrites of DG granule
cells. The axons of these cells (mossy fibers) make synapses on the dendrites of CA3 pyramidal
neurons. The latter send their axons (Schaffer collaterals) to the CA1 region and make synapses on
CA1 pyramidal neurons, the main output neurons projecting to other brain structures, such as the
subiculum. Thus, the hippocampal circuitry directs information flow along the pathway (Figure 2a):
DG granule cells → CA3 pyramidal neurons → CA1 pyramidal neurons. Across CA3 and CA1
subfields, the cell bodies of pyramidal neurons are found in the stratum pyramidale (s.p.), and they
bear apical (orthogonal) and basal dendritic arborizations (Figure 2b). The apical dendrites have a
large shaft extending through the stratum radiatum (s.r.) up to the stratum lacunosum-moleculare
(s.l.m.). Basal dendrites, on the contrary, arborize into the stratum oriens (s.o.). It is worth noting that
the hippocampal unidirectional mainstream of information flow (Figure 2a) resembles the vertical
communication circuit in the retina (Figure 1). In addition to the main tri-synaptic circuit, several local
interneuron loops regulate the activity of principal neurons [44,45].
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ionotropic (AMPA, kainate, NMDA receptors) or metabotropic receptors. AMPA and kainate 
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neurons is regulated by a diverse array of inhibitory interneurons, which can be distinguished on the 
basis of their structural, neurochemical, and electrophysiological features, as well as by the 
membrane district they make synaptic contacts on [18,44,45,50]. For example, cell bodies and axon 
hillocks of pyramidal neurons are targeted by parvalbumin- and cholecystochinin-expressing basket 
cells [51], whereas their dendritic arborizations in the s.l.m. receive synaptic input from 
somatostatin-expressing horizontal s.o. interneurons [52]. Perisomatic and dendritic inhibition play 
different but complementary roles in affecting the activity of pyramidal neurons [53]. 
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Figure 2. Hippocampal circuitry: (a) Signals from the entorhinal cortex (not shown) enter the 
hippocampus through the perforant pathway (PP) fibers, which make excitatory synapses on CA1 
pyramidal neurons (red) and onto granule cells (green) of the dentate gyrus (DG). Granule cells 
make excitatory synapses via mossy fibers (MF) with CA3 pyramidal cells (light blue). The latter 
excite CA1 pyramidal cells via the Schaffer collateral (SC) pathway. The axons of CA1 pyramidal 
cells project to other brain structures, such as the subiculum (not shown). (b) Schematic drawing of a 
CA1 somatostatinergic microcircuit involving an oriens lacunosum-moleculare (O-LM) interneuron. 
This neuron projects to the stratum lacunosum-moleculare, making synaptic contacts with the distal 
dendritic tree of pyramidal neurons. O-LM interneuron is mainly activated by local axon collaterals 
of CA1 pyramidal cells when Schaffer collateral activity drives this cell to its firing threshold. 
3. The Somatostatinergic System in the Retina and in the Hippocampus 
3.1. Retina 
The occurrence of somatostatin in the retina was first demonstrated in extracts of rat retinas by 
radioimmunoassay and bioassay [54,55]. Subsequently, immunohistochemistry experiments 
allowed the retinal cells expressing this peptide to be identified. It is now well-established that 
somatostatin is mainly found in sparsely-occurring, wide-field GABAergic amacrine cells with cell 
Figure 2. Hippocampal circuitry: (a) Signals from the entorhinal cortex (not shown) enter the
hippocampus through the perforant pathway (PP) fibers, which make excitatory synapses on CA1
pyramidal neurons (red) and onto granule cells (green) of the dentate gyrus (DG). Granule cells make
excitatory synapses via mossy fibers (MF) with CA3 pyramidal cells (light blue). The latter excite
CA1 pyramidal cells via the Schaffer collateral (SC) pathway. The axons of CA1 pyramidal cells
project to other brain structures, such as the subiculum (not shown). (b) Schematic drawing of a
CA1 somatostatinergic microcircuit involving an oriens lacunosum-moleculare (O-LM) interneuron.
This neuron projects to the stratum lacunosum-moleculare, making synaptic contacts with the distal
dendritic tree of pyramidal neurons. O-LM interneuron is mainly activated by local axon collaterals of
CA1 pyramidal cells when Schaffer collateral activity drives this cell to its firing threshold.
The three main synaptic stations in the hippocampus (DG, CA3, CA1) mediate transmission
by using glutamate as an excitatory neurotransmitter. As in retinal circuitry, glutamate activates
either ionotropic (AMPA, kainate, NMDA receptors) or metabotropic receptors. AMPA and kainate
receptors mediate fast synaptic transmission, whereas NMDA receptors are involved in synaptic
plasticity [46], although recent d ta indicate that calcium-per eable AMPA receptors m y also play a
role n LTP [47]. Loc l circu ts are driven by GABAergic inhib tory i terneurons, which are essential
for the appropr ate functioning of princ pal neurons [44]. GABA activates either ionotropic (GABA-A)
r metabotropic (GABA-B) receptors. The former med ates fast inhibito y postsynapti transmission,
and the latter mediates slow inhibitory transmission [48,49]. The activity of principal neurons is
regulated by a diverse array of inhibitory interneurons, which can be distinguished on the basis of
their structural, neurochemical, and electrophysiological features, as well as by the membrane district
they make synaptic contacts on [18,44,45,50]. For example, cell bodies and axon hillocks of pyramidal
neurons are targeted by parvalbumin- and cholecystochinin-expressing basket cells [51], whereas their
dendritic arborizations in the s.l.m. receive synaptic input from somatostatin-expressing horizontal
s.o. interneurons [52]. Perisomatic and dendritic inhibition play different but complementary roles in
affecting the activity of pyramidal neurons [53].
3. The Somatostatinergic System in the Retina and in the Hippocampus
3.1. Retina
The occurrence of somatostatin in the retina was first demonstrated in extracts of rat retinas by
radioimmunoassay and bioassay [54,55]. Subsequently, immunohistochemistry experiments allowed
the retinal cells expressing this peptide to be identified. It is now well-established that somatostatin
is mainly found in sparsely-occurring, wide-field GABAergic amacrine cells with cell bodies in the
INL and by “displaced” amacrine cells with cell bodies located in the GCL (Figure 3) (e.g., [56–60]).
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Somatostatinergic wide-field amacrine cells are distributed at very low density to all retinal regions,
while the population of displaced amacrine cells is confined to the ventral retina. Approximately 5% of
GABAergic amacrine cells co-express somatostatin in the larval tiger salamander retina [61]. In cats,
less than 0.1% of all amacrine cells show somatostatin-like immunoreactivity [62]. In spite of the very
sparse distribution of somata, SRIF-containing arborizations, characterized by multiple varicosities,
are extensively distributed throughout the IPL (Figure 3) in all retinal regions (e.g., [59,60]), suggesting
a diffuse action of somatostatin in the retinal circuitry. This is further supported by the widespread
distribution of somatostatin receptors (see below). It is noteworthy that the majority of synaptic contacts
of somatostatinergic amacrine cells occur with processes of other amacrine cells [62]. Although most
amacrine cells possess no axon, those containing somatostatin often have long “axon-like” processes,
which probably function as true axons [58]. In rodent retina, SRIF-containing amacrine cells, like most
amacrines, are under the control of the rod pathway [63]. In chick retina, changes in somatostatin
immunoreactivity are driven by the light–dark cycle [64]. However, the functional properties of retinal
somatostatinergic interneurons are poorly understood. In particular, it is not known whether they
are spontaneously active, as is the case for other amacrine cells, such as dopaminergic ones [65,66].
Recently, major interactions have been determined between SRIF- and dopamine (DA)-releasing
amacrine cells in the non-image-forming visual circuit of the mouse retina [67]. In a few species,
somatostatin immunoreactivity has also been identified in sparse ganglion cells [59].
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Figure 3. Retinal somatostatinergic interneurons. Photomicrographs of a displaced amacrine cell 
immunolabelled for somatostatin (avidin-biotin-peroxidase technique) at two depths. Cytoplasmic 
processes extensively arborize into a meshwork of interwoven varicose fibers at two different levels 
(A, B) in the IPL. Scale bar, 30 µm. Modified from [68]. 
Somatostatin produces its effects by activating five heptahelical transmembrane G-protein 
coupled receptors (GPCRs), named SST1–SST5 [2]. Somatostatin receptors have been 
immunohistochemically localized to different retinal cell populations, suggesting that somatostatin 
may act at multiple levels of the retinal circuitry, and, in particular, in both OPL and IPL [59]. SST1 is 
expressed by SRIF-containing amacrine cells, and it is believed to work as an autoreceptor that 
regulates somatostatin release [68–72]. SST1 is also expressed by some rat ganglion cells [69] and 
dopaminergic amacrine cells [68]. SST2 occurs in two isoforms, SST2A and SST2B [2]. SST2A is 
abundantly expressed and localized predominantly to cone photoreceptors, rod bipolar cells, 
horizontal cells, and to specific amacrine cell populations, including dopaminergic and glycinergic 
ones [59,60,73,74]. The localization of SST2A in the axon terminals of rod bipolar cells suggests that 
somatostatin may regulate glutamate release (see Section 4.1). In humans, SST2A immunoreactivity 
has been found in all retinal layers [75]. The SST2B isoform is mainly localized in the membrane of 
photoreceptors, indicating that somatostatin has activity in the outer retina [76]. No data are 
available about the occurrence of SST3 in the mammalian retina [2,77]. In the newt retina, SST3 has 
been detected in the inner segment of cones and in the connecting cilia of rods, which correspond to 
the outer photoreceptor segments [78]. This is in agreement with the demonstration that SST3 is 
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Somatostatin produces its effects by activating five heptahelical transmembrane G-protein coupled
receptors (GPCRs), named SST1–SST5 [2]. Somatostatin receptors have been immunohistochemically
localized to different retinal cell populations, suggesting that somatostatin may act at multiple levels of
the retinal circuitry, and, in particular, in both OPL and IPL [59]. SST1 is expressed by SRIF-containing
amacrine cells, and it is believed to work as an autoreceptor that regulates somatostatin release [68–72].
SST1 is also expressed by some rat ganglion cells [69] and dopaminergic amacrine cells [68]. SST2 occurs
in two isoforms, SST2A and SST2B [2]. SST2A is abundantly expressed and localized predominantly
to cone photoreceptors, rod bipolar cells, horizontal cells, and to specific amacrine cell populations,
including dopaminergic and glycinergic ones [59,60,73,74]. The localization of SST2A in the axon
terminals of rod bipolar cells suggests that somatostatin may regulate glutamate release (see Section 4.1).
In humans, SST2A immunoreactivity has been found in all retinal layers [75]. The SST2B isoform is
mainly localized in the membrane of photoreceptors, indicating that somatostatin has activity in the
outer retina [76]. No data are available about the occurrence of SST3 in the mammalian retina [2,77].
In the newt retina, SST3 has been detected in the inner segment of cones and in the connecting cilia
of rods, which correspond to the outer photoreceptor segments [78]. This is in agreement with the
demonstration that SST3 is localized in the neuronal cilia in many brain regions, in which it might
play a role as chemical sensor [79] or in ciliary trafficking [80]. SST4 is localized in the ganglion cells
Int. J. Mol. Sci. 2019, 20, 2506 6 of 31
in both mouse [60,67] and rat [81] retinas. In purified ganglion cell culture, immunolabeling occurs
over somata and dendrites [81]. SST5 is found in dopaminergic, cholinergic, and GABAergic amacrine
cells in the inner retina [82], in horizontal cells of the outer retina [83], and also in a subset of ganglion
cells [84]. Somatostatin receptor activation leads to the modulation of different signaling pathways
(Section 3.3).
3.2. Hippocampus
The presence of somatostatin in the hippocampus was first demonstrated through a specific
radioimmunoassays on rat brain samples [85]. Subsequent immunohistochemistry studies confirmed
the occurrence of SRIF-positive neurons in all hippocampal subfields (e.g., [86–89]). It is now known
that somatostatin is expressed by specific subsets of inhibitory interneurons, which also contain GABA
(e.g., [90,91]). As recalled above (Section 2.2.), there is an incredible variety of GABAergic interneurons
in the hippocampal circuitry [44,45,52]. Somatostatinergic interneurons belong to the subset of dendritic
inhibitory interneurons which target the dendritic domains of principal cells. There are two main
groups of them in CA1 and CA3 subfields: bistratified cells (BiCs) and oriens lacunosum-moleculare
interneurons (O-LMs). These interneurons are most commonly found in electrophysiological studies
on tissue slices [52]. Cell bodies of BiCs are located in s.p. and s.o., where their dendritic tree arborizes
horizontally, whereas their axon branches in s.o. and s.r., where they target both the basal and apical
dendritic districts without synapsing the cell bodies of principal cells. O-LMs are horizontal cells
located in the s.o. (Figure 2b). They have dendritic arborizations running horizontally in s.o. and emit
an axon extending to s.l.m., where it branches heavily and targets the distal apical dendritic tree of
CA1 pyramidal cells (Figures 2b and 4). O-LMs are the most studied hippocampal interneurons, as
they drive prototypical feedback inhibition on pyramidal cells and participate in hippocampal theta
(6–10 Hz) activity [44,45,52,92]. In CA1, O-LMs represent about 4.5% of all interneurons. An intriguing
property of these neurons is their spontaneous activity, which would likely provide a tonic inhibition
on pyramidal cells [93,94]. In the CA1 subfield, O-LMs receive major excitatory input from local,
recurrent axon collaterals of pyramidal neurons [44,52] (Figure 2b). The O-LM equivalent in DG is
the hilar perforant pathway-associated cell [44]. It is noteworthy that somatostatinergic terminals
are mainly located at the distal part of the dendrites of DG granule cells and CA3/CA1 pyramidal
neurons [95,96] (Figure 4), whereas somatostatin receptors occur throughout the dendritic tree and cell
bodies of principal neurons (see below).
With the exception of SST5, all of the somatostatin receptor subtypes have been detected in the
hippocampus [97,98]. Despite the overlapping distributions, they show a high degree of specialization
with regard to their subcellular targeting. In CA1 of the mouse hippocampus, SST1 immunoreactivity
is found to be associated with cell bodies of pyramidal neurons and with fibers of s.r. and neuropils
of s.l.m., indicating pre- and post-synaptic localization [99]. SST1 and somatostatin co-localize in
somatostatinergic interneurons in s.o., suggesting a role for SST1 as an autoreceptor [99]. Indeed,
blocking SST1 induces a considerable increase in the hippocampal somatostatin level without affecting
the GABA level [100]. In rats, SST1 occurs in the DG granule cell layer and in the s.p. and s.o. of
the CA3 and CA1 subfields [96]. Diffuse SST2A immunolabeling is detected in DG, whereas the
CA3 region is negative [96]. In rat CA1 pyramidal neurons, SST2A is associated with cell bodies
and basal (s.o.)/apical (s.r.) dendrites, as well as with axon terminals in the s.r. (Schaffer collaterals),
suggesting pre- and post-synaptic effect of somatostatin [101]. SST3 is expressed in all hippocampal
subfields, does not localize to pre- or post-synaptic sites, and is selectively associated with nonmotile
neuronal cilia [79,102,103]. The occurrence of SST3 in these structures suggests that it may work
as a chemical sensor. Interestingly, SST3-KO mice show deficits in object recognition memory and
impairment in adenylyl cyclase (AC)/cyclic adenosine monophosphate (cAMP)-mediated LTP in the
CA1 hippocampus [104]. Finally, SST4 immunolabeling is detected in all hippocampal subfields [96].
In rat CA1 pyramidal neurons, SST4 occurs almost exclusively on the apical dendrites in s.r. where
Schaffer collaterals end and in their somata, suggesting a postsynaptic function [105]. As was nicely
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pointed out by Qiu et al. [106], these neurons are “virtually coated with somatostatin receptors,
suggesting that somatostatin is an important signaling molecule in this region”.
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3.3. Signal Transduction Mediating Somatostatin Action
Somatostatin acts through its receptors (SSTs) by affecting G-protein-mediated intracellular
signaling pathways, which include specific molecular components [2]. Typically, SSTs signal through
Gi/Go proteins, heterotrimeric guanine-nucleotide-binding proteins characterized by sensitivity to
pertussis toxin (PTX), and inhibitory coupling to adenylyl cyclase (AC). The latter is the enzyme
responsible for the production of the second messenger, cAMP, which activates protein kinase A
(PKA). Thus, canonical signal transduction by SSTs mediates inhibitory effects on the AC/cAMP/PKA
pathway [2]. Components of this signaling pathway occur in retinal and hippocampal neurons
(e.g., [107–109]), although specific variations have been described. In the mouse retina, for example,
activation of SST1 or SST2 individually does not affect AC activity. However, by blocking either SST1
or SST2 with specific antagonists, receptor coupling to AC inhibition occurs, suggesting that there
may be interactions between SST1 and SST2 [110]. Further complexity of the signal transduction
cascade is provided by modulatory mechanisms that enhance or reduce the effect of SST activation.
In the CA1 pyramidal neurons of the mouse hippocampus, Ser/Thr protein phosphatase activity
regulates somatostatin signaling [111]. In addition to the AC/cAMP/PKA pathway, other intracellular
enzymatic cascades may mediate the effects of somatostatin. In retinal ganglion cells, SST4 activation
is signaled by Gβγ and protein kinase C (PKC) pathways [112]. In rat hippocampal neurons
maintained in culture, prolonged exposure to somatostatin activates G-protein-coupled receptor
kinase (GRK) and PKCε [113]. Moreover, somatostatin dampens firing in CA1 pyramidal neurons by
downregulating the cyclooxygenase 2 (COX-2)/prostaglandin E2 (PGE2) pathway in a mouse model of
epileptiform bursting [114]. In a nutshell, intracellular pathways driven by SSTs may vary considerably.
This diversification is a hallmark of the somatostatin action (pleiotropic effects: [115]). Retinal ganglion
cells provide an excellent example of the functional diversification stemming from multiple intracellular
signaling. These neurons express both SST4 and SST5 (Section 3.1.): when activated by somatostatin,
SST4 signals to voltage-gated Ca2+ channels via the Gq-PKC pathway [112], whereas SST5 signals
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to AMPA receptors via Gi/o–cAMP–PKA [84]. An important open issue is the receptor–receptor
interactions at the level of either receptor proteins or intracellular signaling. There is increasing
evidence for this type of molecular mechanism to explain the modulatory effect of somatostatin in
both the retina and hippocampus (e.g., [70,106,116,117]). Dissecting out the molecular physiology of
somatostatin receptors will provide new insight into the somatostatin action in neural networks.
3.4. The Complexity of Somatostatin-Based Signaling: Autocrine, Paracrine, and Synaptic Communication
Somatostatin is stored in intracellular vesicles and is secreted through a calcium-dependent
mechanism [118–120]. However, once released, somatostatin is involved in different aspects of cellular
communication, encompassing basically all known signaling mechanisms that may occur inside a neural
network. Somatostatinergic interneurons express a specific receptor, SST1, which regulates somatostatin
release [70,71,99,100]. This autocrine mechanism affects the level of somatostatin, as demonstrated
in SST1-KO mice [70] or by blocking SST1 pharmacologically [100]. On presynaptic membranes,
somatostatin depresses the release of excitatory neurotransmitters through an effect on voltage-gated
calcium channels (see Section 4). In this way, somatostatin influences the synaptic communication
between neurons by acting not through the mechanism of synaptic integration, but through the
modulation of synaptic transmission mediated by classical neurotransmitters. Somatostatin may
also diffuse out of the synaptic space and reach nearby molecular targets in the postsynaptic neuron
as well as in adjacent neurons. This paracrine signaling has its best experimental support by the
observation that the distribution of SSTs exceeds the somatostatinergic synaptic terminals (see Section 3).
In mammalian retina, SSTs occur throughout all layers and are also expressed by photoreceptors
and bipolar cells [59,60]. It is noteworthy that the weft of SRIF-containing processes is not densely
woven (Figure 3), a structural feature suggesting slow, diffusion-limited activity of somatostatin on
retinal neurons [62]. In the hippocampus, somatostatin terminals are mainly located close to the
distal dendrites of the principal neurons in DG, CA3, and CA1 [44,95,96]. However, SSTs are also
found in other subcellular districts. In CA1, for example, SSTs occur not only in the apical dendritic
arborizations but also along the main dendritic shaft and cell bodies of pyramidal neurons as well as
on the axon terminals of Schaffer collaterals [101,105]. In other words, there is a mismatch between the
location of somatostatin and its receptors, suggesting that released somatostatin must spread over
several micrometers to reach SSTs [40]. What is the significance of this paracrine communication?
One possibility is that it allows overcoming the structural burden provided by point-to-point synaptic
contacts. Indeed, it is likely that somatostatin release occurs mainly in extra-synaptic sites [39,40,121].
Released somatostatin has a half-life of several minutes before being degraded by tissue peptidases
(e.g., [122,123]). Thus, it may reach different membrane districts of target cells to drive regulatory
actions and to control the activity of large and diverse neuron populations [124] (see Section 4).
It is important to recall that in the retina, paracrine signaling is not an exclusive feature of the
somatostatinergic system. Upon light stimulation, dopaminergic amacrine cells release GABA and DA
extrasynaptically, acting at a distance via diffusion to control the adaptation of the retinal circuitry to
light [125]. Since somatostatinergic amacrine cells are driven by the rod pathway, there is an interaction
between these two paracrine signaling systems (SRIF and DA) to regulate light adaptation [63].
4. Molecular and Cellular Physiology of Somatostatin Action: Modulation of Membrane
Excitability and Neurotransmission
Early indications that somatostatin could influence neuron activity came from intracellular
recordings with sharp microelectrodes in rat tissue slices (e.g., [126]) and extracellular recordings
of single units in the rat brain (e.g., [127]). Later on, the development of the patch-clamp [128] and
calcium-imaging [129] techniques allowed researchers to characterize the effects of somatostatin on
membrane conductance and intracellular Ca2+ signals in a variety of tissues, including the retina and
hippocampus. There is now an overwhelming set of data indicating that somatostatin targets specific
proteins underlying membrane excitability and neurotransmission. In this way, somatostatin affects
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two key aspects of neuron functioning, namely the ability to produce electrical signals and the ability
to transfer information.
4.1. Retina
A reasonably large variety of ion channels are present in retinal cells, where they play a key role
in transforming visual cues into specific electrical activity. By modeling the membrane currents of the
rod photoreceptor inner segment according to the Hodgkin and Huxley equations, Kamiyama and
collaborators (1996) determined that different types of ion channels are involved in shaping the voltage
response to light after the initial transduction events [130]. Also, in bipolar cells, membrane electrical
responses depend on the interplay of several ion channels [26,131]. In ganglion cells, the output
neurons of the retina, ion channels underlie action potential firing, a fundamental process for relaying
information to the thalamus. Given the importance of ion channels in the physiology of retinal circuitry,
it is not surprising that somatostatin exerts a modulatory action on these membrane proteins, affecting
cell activity and signal processing.
In retinal cells, a common motif of the somatostatin action is the alteration of Ca2+ influx through a
modulatory effect on voltage-gated calcium channels. Akopian and collaborators (2000) first showed the
effects of somatostatin on voltage-gated L-type calcium channels (CaV(L)) in rod and cone photoreceptors
of the salamander retina [132]. The effect differs between the two photoreceptor types: in rods, calcium
currents are reduced, whereas in cones they are augmented. Consistent with the electrophysiological
results, Ca2+ accumulation is inhibited in rods and enhanced in cones [132]. Interestingly, the effect of
somatostatin on CaV(L) in cultured chicken cone photoreceptors is dependent on the circadian phase,
being inhibitory during the night but not during the day [133]. In bipolar cells isolated from goldfish,
somatostatin is able to suppress calcium currents [134]. By analyzing intracellular calcium levels
in rod bipolar cells (RBCs) isolated from rat retina, Johnson and collaborators (2001) showed that
somatostatin affects calcium influx by exerting an inhibitory effect on CaV(L) [135]. Also, in rabbit RBCs,
calcium-imaging experiments demonstrated that Ca2+ accumulation upon membrane depolarization
is depressed by inhibiting CaV(L) through SST2 activation [136] (Figure 5). In rat retinal ganglion
cells, stimulation of SST4 with somatostatin or its specific agonist, L-803,087, reduces L-type Ca2+
current [67,81,112].
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Somatostatin also affects voltage-gated potassium channels in retinal cells. In both rod and cone
photoreceptors of salamander retina, somatostatin potentiates a delayed rectifier K+ current (KV)
but not the Ca2+-dependent K+ current (KV(Ca)) [132]. In rabbit RBCs, on the contrary, the latter
was reduced following specific stimulation of SST2A with octreotide, a somatostatin analog [136].
This effect, however, was likely due to a reduction in Ca2+ influx, since somatostatin inhibits calcium
channels in these neurons [135,136]. Interestingly, in rabbit RBCs, delayed rectifier K+ current
was not affected by somatostatin [136]. In rat retinal ganglion cells, activation of SST4 receptors
potentiated a 4-AP-sensitive, voltage-gated K+ current [81]. Also, in another subset of ganglion cells,
the melanopsin-containing intrinsically photosensitive retinal ganglion cells (M1 ipRGCs), somatostatin,
or the SST4 agonist, L-803,087, produced an increase in voltage-gated potassium currents and reduced
the intrinsic spontaneous firing rate [67].
To modulate ion channel functioning, somatostatin acts via specific G protein-mediated
intracellular pathways, which may differ significantly according to the SST expressed in target
cells [115]. In photoreceptors of the salamander retina, the effect of SST2 activation on KV and CaV(L)
is blocked by PTX, an inhibitor of Gi/o protein, and reduced by intracellular infusion of GDP-β-S,
a non-hydrolysable inhibitor of Gα proteins [132]. On the contrary, modulation of CaV(L) by SST4
activation is not sensitive to PTX but to pharmacological inhibition of the Gβγ complex or PKC in rat
retinal ganglion cells [112]. Remarkably, the effects on Gβγ and PKC were additive, suggesting that
two distinct intracellular pathways were activated by SST4.
What is the biological significance of the modulatory action of somatostatin on ion channels in
retinal cells? To answer this question, let us consider the following signaling pathway for which we
have detailed information: rod photoreceptor (RP) → rod bipolar cell (RBC) → ganglion cell (GC)
(Table 1). This is clearly a simplification, because in mammals, RBCs relay information to ganglion cells
indirectly through a specific circuit between RBCs, AII amacrine cells, and cone bipolar cells [21,63].
In addition, there are several parallel information lines underlying coding of visual information in the
mammalian retina [137]. For the purpose of our reasoning, however, the analysis of the pathway RP →
RBC → GC can give us some interesting hints.
Table 1. Ion channels and their modulation by somatostatin (↑: potentiation; ↓: reduction; = no effect)
in the retinal cells of the information transmission line RP → RBC → GC.
Ion Channels Rod Photoreceptor Rod Bipolar Cell Ganglion Cell
NaV * * =
CaV(L) ↓ ↓ ↓
KV ↑ = ↑
KCa = ↓ =
*: not present; CaV(L): voltage-gated L-type calcium channel; KCa: voltage-gated and Ca2+-dependent potassium
channel; KV: voltage-gated potassium channel; NaV: voltage-gated sodium channel.
It is clear from Table 1 that whatever the target cell is, somatostatin tends to reduce the activity of
CaV(L), which is considered a key ion channel in retinal processing [138]. The main consequence of
this effect is a decrease in Ca2+ influx and, therefore, a reduction in the intracellular Ca2+ signal. Since
in RPs and RBCs, synaptic transmission is a Ca2+-dependent process (e.g., [139–141]), the expected
functional consequence of somatostatin action is a reduction in neurotransmitter release. Consistent
with this prediction, glutamate release detected by HPLC is reduced in the presence of somatostatin or
its analog, octreotide, which displays a high selectivity for SST2 in mouse retinal explants [116,142].
In RBCs, calcium-imaging experiments on specific cell districts showed that somatostatin is able to
modulate calcium influx in both axonal terminals and in the cell bodies [135,136]. In RBCs isolated
from rat retinas, immunocytochemical observations indicated that SST2A receptor immunostaining
localizes to the dendrites, cell bodies, axons, and axon terminals [135]. A similar distribution was also
found in RBCs isolated from mice [116] (Figure 5a) and rabbits [136]. As a whole, these observations
support the notion that somatostatin, via the SST2 receptor, is able to exert modulatory control on the
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glutamatergic transmission in RBCs. An analogous mechanism has also been proposed for glutamate
release from photoreceptors [132]. Less understood is the significance of somatostatin action through
its receptors on the dendrites and cell bodies of RBCs. In rat RBCs, CaV(L) is strategically located at axon
terminals to control neurotransmitter release [143–145]. However, somatostatin affects the intracellular
accumulation of Ca2+ in rabbit RBCs in both the terminals and somata [136]. Electrophysiological
recordings from rabbit RBCs with cut axons might help to solve this issue (e.g., [145]). The significance
of the inhibitory effect on CaV(L) and intracellular Ca2+ signaling in retinal GCs, which are output
neurons, is not clear [81]. It is worth noting, however, that M1 ipRGCs act as presynaptic elements for
DA amacrine cells (postsynaptic elements) [146].
In rat retinal GCs, immunostaining for SST4 is localized to dendrites and cell bodies [81]. Unlike
RPs and RBCs, ganglion cells generate fast action potentials to transmit information to the thalamus.
It is then conceivable that somatostatin modulatory action on KV (Table 1) may affect firing activity.
Indeed, specific stimulation of SST4 produces a reduction in the frequency of action potentials induced
by the injection of depolarizing current in GCs [81]. Also, somatostatin and the SST4 agonist L-803,087
reduce the spike frequency in spontaneously active M1 ipRGCs [67]. To our knowledge, there are no
reports of somatostatin acting on voltage-gated sodium channels in retinal GCs. This is an interesting
aspect of the somatostatin effect on membrane excitability: the capability of generating rapid impulses
is preserved, while neuronal information (that is, series of impulses over time) is modulated by the
effects on firing properties, such as the frequency. The significance of the effect on KCa in RBCs (Table 1)
is less clear. According to the modeling of membrane ionic currents proposed by Usui and collaborators
(1996) for bipolar cells [131], KCa is involved, along with other channels, in generating the electrical
responses of these cells. Thus, it is conceivable that the reduction of KCa, even if it is a consequence of
the effect of somatostatin on CaV(L) [136], may significantly affect electrical signaling in RBCs. In this
regard, it is interesting to recall that bipolar cells in teleost retina are capable of producing Ca2+ action
potentials [144] and presynaptic Ca2+ transients [147] in response to light flashes after dark adaptation,
and that Ca2+-activated K+ current is a key component of spiking activity [148].
Somatostatin also targets neurotransmitter receptors in the transmission line RP → RBC → GC.
A patch-clamp recording and calcium-imaging study on a subset of rat retinal GCs showed that
somatostatin suppresses AMPA responses via SST5 receptors through a rather complex intracellular
pathway involving cAMP/PKA and the release of Ca2+ from intracellular stores [84]. AMPA receptors
are the main non-NMDA receptors responsible for ganglion cell activation by glutamate released by
bipolar cells [149].
In addition to principal neurons, somatostatin affects the activity of retinal interneurons.
In organotypic retinal slices, somatostatin enhances GABA-A responses in rat amacrine cells, suggesting
a possible role in facilitating the GABAergic inhibitory transmission in the retinal circuitry [150].
In cultured rat amacrine cells, on the contrary, activation of SST5/SST2 receptors reduces GABA
through the inhibition of voltage-gated Ca2+ channels (L- and N-types) and via negative coupling with
cAMP/PKA signaling pathway [151]. PKA downregulation could reduce the phosphorylation of Ca2+
channels with consequent reduction in Ca2+ influx and GABA release [115]. Somatostatin, through
SST2A, inhibits both K+ and Ca2+ channels and spontaneous firing in mouse dopaminergic amacrine
cells involved in a specific microcircuitry in the inner retina [67].
In summary, the available data suggest that somatostatin affects the functioning of retinal principal
neurons by exerting mainly a dampening effect on information transmission. The goal of this effect is
likely to set the correct dynamic range of neuronal activity in the network (see Section 5.3). Indeed,
the widespread arborization of somatostatinergic amacrine cells suggests that somatostatin “does not
have a role in fine-grain visual information processing in the mammalian retina, but likely modulates
the overall retinal circuitry” [59]. In addition, the electrophysiological studies reported above indicate
that the effects of somatostatin on the functional properties of retinal cells have a slow onset and often
last after its removal (e.g., [132,136]). This slow time course does not match the more rapid processing
of visual information [124].
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4.2. Hippocampus
Early intracellular recordings from CA1 pyramidal neurons in hippocampal slices provided
conflicting results as to the action of somatostatin on membrane excitability (e.g., [152–154]). Soon after,
it became clear that the excitatory effects of somatostatin were actually due to the indirect action on
acetylcholine neurotransmission: somatostatin alone hyperpolarizes hippocampal pyramidal neurons
and depresses their firing (e.g., [155,156]). It is now generally accepted that somatostatin exerts
mainly an inhibitory action on hippocampal principal neurons. Unlike the retina, somatostatinergic
interneurons are found throughout all hippocampal subfields. Among them, CA1 region is the best
studied in terms of somatostatin effect on membrane excitability and neurotransmission. Therefore,
here, we refer mainly to this region.
A general mechanism to produce membrane hyperpolarization and to reduce the firing rate
is the activation or potentiation of membrane K+ currents [157]. Hippocampal pyramidal neurons
express several types of these currents [158], and electrophysiological experiments have shown
that somatostatin targets a non-inactivating, voltage-dependent current known as the M-current
(IM) as well as K+ currents affecting the resting potential [159–162]. The M-current (M stands for
inhibitory muscarinic agonists [158]) counteracts membrane depolarizations and tends to reduce the
firing rate by shifting the membrane potential away from the action potential threshold. By using
somatostatin receptor knock-out (KO) mice and subtype-specific ligands, it has been possible to
demonstrate that the effect on M-current is due to the activation of SST4 [106]. As for the intracellular
signaling cascade, studies suggest that arachidonic acid metabolites mediate IM potentiation through
the activation of phospholipase A2 (PLA2; [161,163]). The M-current has a limited role in setting
the resting potential of hippocampal neurons and therefore does not explain the hyperpolarization
induced by somatostatin [153,159]. As demonstrated by Schweitzer et al. (1998), somatostatin
activates a voltage-insensitive K+ leak current (IK(L)) that exerts a stabilizing effect on the resting
membrane potential of CA1 pyramidal neurons in rat hippocampal slices [162]. In cultured rat
hippocampal pyramidal neurons, a G protein-gated, inwardly rectifying potassium (GIRK) current is
also enhanced by somatostatin, whereas it is inhibited by PTX [164]. GIRK is activated by the Gβγ
subunit of Gi/o and may help to stabilize the resting membrane potential [165]. Finally, somatostatin
induces membrane hyperpolarization and reduces spiking by activating K+ leak channels in mouse
hippocampal slices [111]. Interestingly, somatostatin also affects firing by stimulating the insertion
of pre-formed GIRK channels into the cell membrane [111]. In summary, somatostatin dampens
membrane excitability in CA1 pyramidal neurons by targeting distinct potassium channels that lessen
membrane depolarization, therefore reducing the firing rate (Figure 6).
In addition to regulating single cell excitability, somatostatin plays a major role in controlling
synaptic communication mediated by fast neurotransmitters. In pyramidal neurons freshly dissociated
from the rat hippocampal CA1 region, somatostatin reduces voltage-gated N-type calcium currents
(CaV(N)) via the PTX-sensitive Gi/o protein pathway but without the involvement of AC or cAMP [166].
The significance of this modulation is related to the role of CaV(N) in the regulation of neurotransmitter
release from nerve terminals, that is, somatostatin might reduce glutamate release from the principal
hippocampal neurons. Electrophysiological studies on rat hippocampal slices have demonstrated that
somatostatin reduces both AMPA and NMDA receptor-mediated excitatory postsynaptic currents
(EPSCs) but does not affect GABA-A or GABA-B receptor-mediated inhibitory post-synaptic currents
(IPSCs) in CA1 pyramidal neurons [167]. Pharmacological maneuvers suggested that the effect on
glutamatergic currents is mediated by Gi/o protein through presynaptic mechanisms at CA1 Schaeffer
collateral synapses. Also, in mouse hippocampal slices, somatostatin significantly inhibits both AMPA
and NMDA EPSCs in CA1 pyramidal neurons; however, in this preparation, somatostatin proved to
significantly increase GABAA IPSCs [168]. A patch-clamp study on autapses formed by hippocampal
neurons grown in isolation provided further evidence to support the role of somatostatin in inhibiting
AMPA and NMDA excitatory transmission [169]. In particular, somatostatin and its analogues, seglitide
and octreotide, reduced voltage-gated Ca2+ currents through the activation of presynaptic receptors and
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via PTX-sensitive G proteins. Definitive evidence for the role of somatostatin in inducing the presynaptic
inhibition of glutamate release via SST1 was provided by Bagnoli’s laboratory. By using SST1-KO mice
and selective pharmacological tools, they demonstrated the presynaptic localization of SST1 and the
inhibitory effect of its activation on both AMPA/NMDA responses and glutamate release [99]. They
also found that SST1 activation does not affect GABAergic inhibitory transmission. Other findings have
provided evidence for the involvement of SST2 in inhibiting excitatory transmission at the synapse
between the Schaffer collateral and CA1 pyramidal neuron in rat hippocampal slices [170]. The in vitro
firing rate of these neurons was reduced by the application of octreotide without any significant effect
on membrane potential [170]. In a nutshell, all of these data indicate that somatostatin can reduce
firing activity by attenuating excitatory synaptic transmission. It is worth noting that somatostatin
inhibits dendritic Ca2+ spikes by affecting N-type Ca2+ currents in DG granule cells [171]. Since these
channels play an important role in signal processing in dendritic trees [172–174], somatostatin again
stands out as a neuropeptide that is able to reduce neuronal excitability at multiple levels.
Int. J. Mol. Sci. 2018, 19, x 13 of 32 
 
selective pharmacological tools, they demonstrated the presynaptic localization of SST1 and the 
inhibitory effect of ts activation on both AMPA/NMDA responses and glutamate release [99]. They 
also found that SST1 activation does not affect GABAergic inhibitory transmission. Other findings 
have provided evidence for the involvement of SST2 in inhibiting excitatory transmission at the 
synapse between the Schaffer collateral and CA1 pyramidal neuron in rat hippocampal slices [170]. 
The in vitro firing rate of these neurons was reduced by the application of octreotide without any 
significant effect on membrane potenti l [170]. In a nutshell, all of t ese data indicate th t 
somatostatin can reduce firing activity by attenuating excitatory synaptic transmission.  It is worth 
noting that somatostatin inhibits dendritic Ca2+ spikes by affecting N-type Ca2+ currents in DG 
granule cells [171]. Since these channels play an important role in signal processing in dendritic trees 
[172–174], somatostatin again stands out as a neuropeptide that is able to reduce neuronal 
excitability at multiple levels. 
  
(a) (b) 
Figure 6. Somatostatin reduces the firing rate of mouse hippocampal neurons. Extracellular 
recordings with a sharp microelectrode were performed from the stratum pyramidale of the CA1 
subfield in a tissue slice. (a) Spontaneous firing (Control) was induced by perfusing tissue with 
Mg2+-free medium containing the potassium channel blocker 4-AP. Application of 1 µM somatostatin 
(SRIF) reduced the firing rate. (b) Quantitative analysis for the somatostatin effect shown in (a). 
Somatostatin produced a decrease of ~30% in the frequency of action potentials. * p < 0.05. Modified 
from [114]. 
As a whole, the available data suggest that somatostatin depresses the activity of hippocampal 
pyramidal neurons by acting through pre- and post-synaptic mechanisms. At the presynaptic level, 
somatostatin reduces the release of glutamate, an excitatory neurotransmitter. In term of synaptic 
integration in the postsynaptic neurons, this favors inhibitory input, which, in turn, leads to a 
reduction in firing frequency. At the postsynaptic level, somatostatin stabilizes the membrane 
resting potential and tends to produce damping of depolarizations. In this way, pre- and 
post-synaptic effects of somatostatin act synergistically to reduce the excitability and to induce spike 
frequency adaptation. It is worth noting that there is no evidence for an effect of somatostatin on 
voltage-gated sodium channels in hippocampal pyramidal neurons. Thus, as in the retina, 
somatostatin targets firing properties, that is, it does not impede neurons to communicate, but it 
modulates how neurons communicate. 
Although most of the available information on the activity of somatostatin in the hippocampus 
has been obtained by studying CA1 pyramidal neurons, there are reports suggesting that similar 
mechanisms might also operate in the CA3 region, although the intensity of the effects may vary 
somewhat [175], likely reflecting different expression level of SSTs (e.g., [176,177]). However, there 
are also remarkable differences among subfields. For example, unlike rat CA1 pyramidal neurons, 
somatostatin does not exert any postsynaptic effect on K+ currents in mouse DG granule cells and 
does not affect their firing properties [171]. Variations in somatostatin action across hippocampal 
regions might be related to their specific, local computational tasks. In guinea pig hippocampal 
slices, somatostatin augments LTP at mossy fiber/CA3 neuron synapses but has no effect on LTP in 
Figure 6. Somatostatin reduces the firing rate of mouse hippocampal neurons. Extracellular recordings
with a sharp microelectrode were performed from the stratum pyramidale of the CA1 subfield in a
tissue slice. (a) Spontaneous firing (Control) was induced by perfusing tissue with Mg2+-free medium
containing the potassium chan el blocker 4-AP. Applicat on of 1 µM s matostatin (SRIF) reduced the
firing rate. (b) Quantitative analysis for the somatostatin effect shown in (a). Somatostatin produced a
decrease of ~30% in the frequency of action potentials. * p < 0.05. Modified from [114].
As a whole, the available data suggest that somatostatin depresses the activity of hippocampal
pyramidal neurons by acting through pre- and post-syn ptic mech isms. At the presynaptic level,
somatostatin reduces the release of glutamate, an excitatory neurotransmitter. In term of synaptic
integration in the postsynaptic neurons, this favors inhibitory input, which, in turn, leads to a reduction
in firing frequency. At the postsynaptic level, somatostatin stabilizes the membrane resting potential
and tends to produce d mping of dep larizations. In this way, pre- and post-synaptic effects of
somatostatin act synergistically to reduce the excitability and to induce spike frequency adaptation. It is
worth noting that there is no evidence for an effect of somatostatin on voltage-gated sodium channels
in hippocampal pyramidal neurons. Thus, as in the retina, somatostatin targets firing properties, that is,
it does not impede neurons to communicate, but it modula es how neurons communicate.
Although most of the available information on the activity of somatostatin in the hippocampus
has been obtained by studying CA1 pyramidal neurons, there are reports suggesting that similar
mechanisms ight also operate in the CA3 region, although the intensity of the effects may vary
somewhat [175], likely refl cting differ nt expression level of SSTs (e.g., [176,177]). However, there are
also remarkable differences among subfields. For example, unlike rat CA1 pyramidal neurons,
somatostatin does not exert any postsynaptic effect on K+ currents in mouse DG granule cells and
does not affect their firing properties [171]. Variations in somatostatin action across hippocampal
regions might be related to their specific, local computational tasks. In guinea pig hippocampal
slices, somatostatin augments LTP at mossy fiber/CA3 neuron synapses but has no effect on LTP in
the Schaffer collateral/CA1 pathway [178]. In mouse DG, somatostatin depresses LTP at perforant
path fiber/DG granule cell synapses [171]. It is also possible, as suggested by Baratta et al. (2002),
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that functional differences in somatostatin action between hippocampal subfields may be related
to the specific subcellular localization of SSTs [171]. Finally, species-specific differences may also
be responsible for this variability. For example, unlike results from the rat hippocampus, in mice,
somatostatin does not affect EPSCs in CA1 pyramidal neurons [106]. Table 2 provides a summary
of the main effects of somatostatin on ion channels in the principal neurons along the information
transmission line DG → CA3 → CA1. It is interesting to note that, in the hippocampus, somatostatin
also tends to attenuate neuronal communication by depressing membrane excitability through K+
channels and glutamate release through Ca2+ channels. Therefore, as proposed for retinal circuitry,
it is conceivable that somatostatin plays a key role in setting the operational dynamic range of the
hippocampal principal neurons.
Table 2. Ion channels and their modulation by somatostatin (↑: potentiation; ↓: reduction; = no effect)
in the principal hippocampal neurons of the information line DG → CA3 → CA1.
Ion Channels DG Granule Cells CA3 Pyramidal Neurons CA1 Pyramidal Neurons
NaV = = =
CaV(N) ↓ ↓
KM, KL, GIRK = ↑ * ↑
CaV(N): voltage-gated N-type calcium channel; GIRK: G-protein gated, inwardly rectifying potassium channel; KL:
voltage-insensitive, leak potassium channel; KM: non-inactivating, voltage-dependent potassium channel; NaV:
voltage-gated sodium channel. *: somatostatin causes membrane hyperpolarization, but the identity of K+ channels
is currently unknown.
5. Retina and Hippocampus: Common Themes
In terms of structural organization, the retina and hippocampus differ significantly in terms of
the design of the somatostatin-based system (see Section 3). This clearly reflects both anatomical
constraints and the size of the tissue containing the circuitry. The retina is a flattened structure,
which is ~300 µm thick in humans [179], with principal neurons densely packed in definite layers
(Figure 1a). Somatostatinergic interneurons have cell bodies confined either in the INL or GCL
(“displaced” amacrine cells), but they can easily affect both synaptic stations (IPL and OPL; Figure 7).
The hippocampus, on the contrary, shows a typical convoluted organization, with principal neurons
arranged in layers (as in the retina) and connected through specific bundles of nerve fibers (mossy fibers
and Schaffer collaterals) (Figure 2a). The main synaptic stations (DG, CA3, CA1) are set apart, and
therefore, somatostatinergic interneurons occur in each hippocampal subfield (Figure 7). Nonetheless,
there are features of somatostatin-based signaling shared by both circuitries, suggesting that the
conserved motifs of somatostatin activity are not related per se to the circuitry cytoarchitectonics.
5.1. Co-Transmission of GABA and Somatostatin
In both the retina and hippocampus, somatostatinergic interneurons are inhibitory neurons that
provide mainly a local, parallel pathway that regulates the information flow through principal neurons.
Somatostatinergic interneurons contain both GABA (a classical neurotransmitter) and somatostatin (a
neuropeptide), and therefore, can affect target neurons in different but complementary ways [38–40].
GABA induces postsynaptic events that add up to other synaptic inputs. Somatostatin, on the
contrary, reduces the release of the excitatory neurotransmitter glutamate via presynaptic effects
(see Section 4) [99,116,142,167,169]. Therefore, it attenuates the excitatory postsynaptic events before
they combine with the GABA-mediated ones in the process of synaptic integration. In other words,
somatostatin facilitates the inhibitory action of the classical neurotransmitter GABA [167]. However,
there are several aspects of co-transmission that require keen analysis to fully understand their impacts
on synaptic communication [40,41,121,180]. Although somatostatin, like GABA, is released through a
calcium-dependent mechanism and depends on action potential discharge [118–120], it is not clear
how the activity level (i.e., firing frequency) affects the release of the two transmitter substances
differentially. While classical neurotransmitter release is fairly irrespective of the action potential
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frequency, which mainly affects the postsynaptic response amplitude through synaptic integration,
neuropeptide release requires bursting or high frequency activity [39,40,121]. Hippocampal O-LMs
seem to possess autorhythmic activity [93,94], but the low frequency (about 7 Hz) of spontaneous firing
is likely insufficient to drive somatostatin release [38,40]. Indeed, there are indications that somatostatin
is released under conditions of enhanced electrical activity of the hippocampal neurons [119,120,171].
It is thus conceivable that somatostatin activity might be more important when the firing frequency
is high. Under these conditions, somatostatin potentiates the GABA effect [40,41] and contributes to
setting a cutoff frequency for firing in principal neurons, thus avoiding hyper-excitation. Thanks to
the paracrine signaling mechanism, somatostatin is able to reach neighboring cells to modulate their
activity (see Section 3.4). In this way, co-transmission allows somatostatin-GABAergic neurons to
exert both point-to-point control of postsynaptic neurons as well as more diffuse control of neuronal
microcircuitries [121]. In this regard, it is noteworthy that while classical neurotransmitters are
released at synaptic sites, neuropeptides are released mostly from extra-synaptic sites (dendrites and
axons) [39,40,121]. Although our understanding of GABA-somatostatin co-transmission in retinal
amacrine cells is still limited, it is likely that the general mechanisms outlined above also applied to the
retinal circuitry. The main difference between the hippocampus and the retina is due to the synaptology
of somatostatinergic interneurons (Section 3). While O-LM interneurons make synaptic contacts with
principal neurons (Figure 2b), somatostatinergic amacrine cells interact through conventional synapses
mainly with other amacrine cells [62]. It is likely that GABA-somatostatin co-transmission may target
separate yet interconnected subsets of neurons in the retinal circuitry, with the goal of setting the
activity level of principal neurons. In this regard, it is interesting to note that recent data indicate
that somatostatinergic amacrine cells target both dopaminergic amacrine cells and ganglion cells in a
specific visual microcircuit [67].Int. J. Mol. Sci. 2018, 19, x 15 of 32 
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5.2. Modulation of Ion Channels
Our current understanding of the effect of somatostatin on ion channels in both retinal
and hippocampal circuitries underscores the role of K+ channels as molecular targets (Table 3).
These channels control membrane excitability by counteracting depolarizing currents [157].
The functional goal is to reduce the probability of reaching the firing threshold, and, once spike
discharge has begun, to facilitate the adaptation of the action potential frequency. An intriguing aspect
of this regulation is the molecular diversity of K+ channels targeted by somatostatin (Tables 1 and 2).
Although it is possible to roughly distinguish two main subgroups, that is, channels controlling the
resting potential (KL and GIRK) and channels controlling firing (KV, KM, KCa), this heterogeneity seems
quite odd. A possible explanation can be envisaged by considering that the variety of K+ channels
plays a key role in defining the discharge properties of different neurons [181] and also in regulating the
electrical activity of dendrites [165]. Thus, it is reasonable to conceive that the target for somatostatin is
“the K+ channel”, even though its molecular and biophysical identity may vary considerably according
to the electrical signaling produced by specific neurons. Clearly, by affecting K+ channels, somatostatin
influences neuronal communication and therefore reduces the level of network activity.
Table 3. The somatostatinergic system in the retina and hippocampus: shared properties and
mechanisms (↑: potentiation; ↓: reduction) along the main line of information transfer (retina: RP →
RBC → GC; hippocampus: DG → CA3 → CA1).
Retina Hippocampus Significance
SRIF interneuron
Co-transmitter GABA GABA Fast synaptic inhibition in microcircuits
Autoreceptor SST1 SST1 Control of somatostatin secretion
SRIF receptors
Distribution Wide Wide Diffuse (over several µm) and global action
Presynaptic neurons SST2 SST1/SST2 Targets calcium channels
Output neurons * SST4 SST4 Targets potassium channels
SRIF action on glutamatergic
neurotransmission
Presynaptic site Ca2+ channels (↓) Ca2+ channels (↓) ↓ neurotransmitter release
Postsynaptic site K+ channels (↑) K+ channels (↑) ↓ firing rate
SRIF signaling Global action Inhibitory Inhibitory Network stabilizer
SRIF: somatostatin; SST: somatostatin receptor. *: retinal ganglion cells and CA1 pyramidal cells.
Another common motif of somatostatin activity is the inhibitory effect on voltage-gated Ca2+
channels (Table 3). The significance of this modulation is to produce a reduction in the presynaptic
release of glutamate, the excitatory neurotransmitter in the main line of information transfer in both the
retina and hippocampus. In other words, somatostatin tends to depress glutamatergic transmission.
The outcome is again a “braking” effect on network activity. Although voltage-gated Ca2+ channels
may exhibit molecular and biophysical heterogeneity across different neuronal types (Tables 1 and 2),
it worth mentioning that both CaV(L) and CaV(N) are high-voltage activated calcium channels, which are
typically involved in regulating calcium-dependent neurotransmission [182].
On the basis of the widespread distribution of SSTs and the effects on ion channels, it is conceivable
that somatostatin does not mediate a point-to-point action, but rather, it affects the excitability of the
whole network “globally”. The available data suggest that, at least in the hippocampus, somatostatin
release is enhanced under conditions of increased activity [119,120]. Thus, it is tempting to speculate that
somatostatin impedes principal neurons from becoming over-responsive by reducing their excitability
with consequent damping of the firing rate. In other words, somatostatin works as homeostatic
regulator of network activity.
5.3. The Logic of Somatostatin-Based Signaling
The retina and hippocampus differ in terms of their specific functional goals. Visual stimuli are
processed by the retina in a rather complex way to make the firing of the ganglion cells informative
(sensory coding) for the thalamus (e.g., [22,137,183–185]). The hippocampus, on the other hand,
is a circuitry organized to handle highly-processed sensory information from other brain circuits and
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to play roles in learning and memory (e.g., [186–190]). Despite these differences in computational
tasks, both the retina and hippocampus rely on somatostatin to assure the proper functioning of
their circuitries. This is obtained through common molecular and cellular mechanisms that lead to
a “braking” effect on the activity of principal neurons. Thus, the somatostatinergic system works
as a network stabilizer. Several experimental and clinical observations support this notion. In the
rabbit retina, somatostatin acts on the whole retinal circuitry to improve the ganglion cell output
over a long-lasting timescale, thus assuring stability in visual processing [124]. In SST1-KO mice, the
retinal level of somatostatin increases, and SST2 becomes overexpressed [70]. As a consequence of this
“disturbance” in the somatostatinergic system, electroretinograms (ERGs) recorded in response to light
flashes display altered oscillatory potentials (OPs) [191]. Since OPs are likely generated by bipolar
cells [192], OP alterations suggest a malfunctioning of the vertical circuit of information flow (Figure 1b)
in the presence of disrupted somatostatin signaling. It is noteworthy that somatostatinergic amacrine
cells represent only a small percentage of the whole retinal cell population [61,62], yet disruption in
their signaling affects network functionality. Evidence for a role of somatostatin in setting the level of
neuronal activity irrespective of visual processing was provided by Vuong et al. (2015). In the mouse
retina, somatostatin plays a compensatory role in a non-image-forming visual circuit involving DA
amacrine cells and M1 ipRGCs: by adjusting the retinal DA level, somatostatin assures the stability
of the light response by M1 ipRGCs, avoiding excessive firing [67]. The role of somatostatin in the
etiopathogenesis of epilepsy is a further example of how this peptide is required to maintain network
stability. It is well known, in fact, that the loss of somatostatinergic interneurons in the dentate
gyrus contributes to epileptogenesis, and the administration of somatostatin has shown antiepileptic
properties [193]. Electrophysiological studies on in vitro models of epilepsy have provided evidence
that somatostatin acts in CA1 and CA3 to reduce hyper-excitability [175]. In hippocampal CA1
pyramidal neurons, spontaneous epileptiform bursting is significantly reduced by somatostatin
through the activation of SST4 coupled to an increase in the M-current [106]. In a nutshell, somatostatin
exerts a “braking” action on the functioning of network principal neurons; by exploiting its effects on
membrane excitability and neurotransmission, and due to its property of being a diffusible substance
(paracrine signaling; Table 3), somatostatin creates a microenvironment inside the network that drives
neurons to work under “low-pass filter” conditions in terms of their firing frequency.
Somatostatinergic neurons are not the only interneurons capable of exerting inhibitory control.
In the retina, both horizontal cells and amacrine cells mediate feedback and feedforward inhibition in
OPL and IPL [12,30,194]. In addition, many different types of amacrine cells occur in the mammalian
retina, adding further complexity to the inhibitory system [12,37]. In the hippocampus, GABAergic
interneurons are remarkably diverse, both morphologically and physiologically [44,45,195]. Besides
their structural properties and anatomical organization, an amazing feature of inhibitory interneurons
in both the retina and hippocampus is their neurochemical heterogeneity, which depends mostly
on the presence of a second “modulatory” transmitter in addition to the classical fast inhibitory
neurotransmitters (GABA or glycine). In the retina, several neuropeptides have been identified in
subsets of amacrine cells including substance P, neuropeptide Y (NPY), vasoactive intestinal peptide
(VIP), and cholecystokinin (CCK), just to mention a few [32,196]. Also, hippocampal interneurons may
express NPY, CCK, and VIP [44]. Like somatostatin, but unlike fast neurotransmitters, neuropeptides act
over a slow timescale and a wider space outside the synaptic cleft [39,40,121]. Why do neural networks
require so many diverse inhibitory interneurons, and why do they rely on synaptic mechanisms
operating on complementary timeframes (co-transmission)? To explain this riddle, we have to consider
that inhibition is fundamental for the production of specific computational tasks characterizing different
neural networks. In the retina, lateral information flow is controlled by inhibitory interneurons
(horizontal cells and amacrine cells) to allow visual processing to occur. For example, horizontal
cells play a key role in establishing center-surround organization to the receptive fields of bipolar
cells by producing surrounding inhibition in the OPL. These receptive fields are further shaped in
terms of both spatial and temporal characteristics by the activity of amacrine cells, which are key
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regulators of ganglion cell activity (e.g., [12,30]). In the hippocampus, GABAergic interneurons control
synaptic integration and spike initiation in pyramidal cells, thus shaping the timing of afferent and
efferent information flow. In addition, they produce synchronization of local cortical circuits; in short,
inhibitory interneurons affect the network dynamics [17,44,197]. Thus, the remarkable anatomical,
neurochemical, and physiological diversity of inhibitory interneurons matches the complexity of
network functioning because they are required for several computational tasks.
Given the great variety of inhibitory interneurons, what is so special about somatostatinergic
interneurons? Although basically all inhibitory interneurons share the property of braking the excessive
activity of principal cells, we are tempted to speculate that somatostatin may represent a unique
modulatory substance that is able to affect not only network dynamics but also network physiology.
In this review, we have addressed the role of somatostatin as a regulator of information transmission
between neurons. However, somatostatin receptors are also expressed by other cellular types in
the same tissue housing the neuronal network. For example, somatostatin-binding sites as well
as SST mRNAs have been detected in astrocytes [198–200], suggesting that somatostatin may exert
biological actions on these glial cells. Indeed, pharmacological assays have shown that somatostatin
inhibits endozepine release in cultured rat astrocytes through the activation of SST1, SST2, and SST4
negatively coupled to the canonical transduction pathway AC/cAMP/PKA [201]. Also, a recent
paper by Carmignoto’s laboratory [202] provided compelling evidence that somatostatin-expressing
interneurons affect intracellular Ca2+ signaling through SST4 in adult cortical astrocytes. Glia-neuron
crosstalk plays a key role in nervous tissue physiology, being involved in diverse processes, such
as volume regulation, metabolism, and information flow [203,204]. Thus, findings on the effect of
somatostatin on astrocytes underscore the importance of this neuropeptide for the general functioning
of the network. It is worth noting that fibers of the predominant glial cell in the retina, the Müller
cell, have been reported to be immunoreactive for SST1 and SST2 [69]. SSTs, in particular, SST2,
also occur in the endothelial cells of blood vessels [2] and exert antiangiogenic effects, preventing
pathological neovascularization in several experimental models (e.g., [205–209]). Somatostatin has
been proven to counteract the dysregulation of pro-angiogenic factors that characterize diabetic
retinopathy [63,196,210]. The involvement of somatostatin in so many diverse processes, such as the
regulation of astrocyte functioning and vascularization processes, is understandable by considering
that this neuropeptide works through the activation of different receptors (SST1–5), which, in turn,
are coupled to different signaling pathways. The diversification of the intracellular signaling cascades
is responsible for “the pleiotropic cellular functions” of somatostatin [115]. In summary, experimental
observations suggest that somatostatin released by somatostatinergic interneurons is important not
only for the correct functioning of the neuronal network, but also for the maintenance of the milieu in
which neurons work (Figure 8).
While somatostatin is a key molecule that is able to control many diverse aspects of neuronal tissue
physiology, clearly, it cannot regulate all of the cellular processes underlying the complex functioning of
a living tissue. Indeed, other peptidergic systems are known to operate in neural networks. For example,
an NPY-based system occurs both in the retina [211] and the hippocampus [212]. The available data
support the notion that neuropeptidergic systems work as neurochemical devices that complement
and balance each other’s actions [213]. In the developing retina, for example, neuropeptides play
a role not only in regulating network growth but also in modulating network activity according to
specific timeframes before and after eye opening [214]. To make the matter even more complicated,
neuropeptides may also co-localize in the same interneurons. For instance, many GABAergic neurons
contain both somatostatin and NPY in hippocampus DG [212]. Understanding how peptidergic
systems coordinate their activities to regulate network functioning represents an unsolved yet exciting
issue in the field of neuroscience [121,215].
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6. The Role of Somatostatin in Network Functioning: Implications for Health and Disease
After several years of studies, there is now overw elming evidence that somatostatin plays a key
role in the functioning of retinal and hippocampal networks. By modulating membrane excitability
and neurotransmitter release, somatostatin contributes sig ificantly to setting the level of activity
of principal neurons. The occurrence f somatostatin receptors in different cellular types further
underscores the importa ce of this neuropeptide, not only in the regulation of neuron activity but also
in the general physiology of the tissue housing neural networks. Indeed, disturbance in somatostatin
signaling is a hallmark of many brain diseases, including disorders of the retina and hippocampus
(e.g., [8,44,63,77,115,193,196,216–218]). With this premise, it is n t surprising that the somatostatinergic
system has attracted the interest of researchers aimed at finding adequate t erapeutic solutions for
debilitati g diseases such as diabetic retinopathy nd epilepsy.
In the reti a, there is increasing evidence that somatostatin may act as a neuroprotective
agent against ischemic insults, although the mechanism underlying its protecting effect is far
from being clarified [63,77,196,219]. Several observations suggest that som tost tin may meliorate
neurodegeneration consequent to ischemia by inhibiting glutamate release in the retinal circuitry,
an event that would occur through presynaptic SST2 [116]. Further support for the involvement of SST2
in mediating somatostatin neuroprotective activity has been provided by studies on SST-KO retinas.
The retinal response to ischemia is significantly spared in the presence of SST2 overexpression, as in
SST1-KO animals, whereas it is drastically increased when SST2 has been knocked out [191,220,221].
Somatostatin has been also shown to avoid high glucose-associated neurodegeneration in the
retina, as demonstrated in rat models of diabetic retinopathy, in which somatostatin eye drops
prevented functional abnormalities (as assessed by ERG) and inhibited glutamate accumulation [222].
More recently, somatostatin topical administration was tested in clinical trials and proved useful in
avoiding the progression of pre-existing retinal neurodysfunction [223].
In the hippocampus, several studies have provided evidence for a role of somatostatin in
depressing the neuronal hyper-excitability underlying seizures (e.g., [106,175]). Direct injection of
somatostatin into the hippocampus produced a strong inhibitory effect on behavioral and electrical
seizures recorded in vivo [216]. Alterations in the somatostatinergic system have been documented in
virtually all experimental models of temporal lobe epilepsy (TLE) [96,193,216,224]. A loss of neurons
expressing somatostatin has been demonstrated in the hippocampus of patients with TLE [225,226].
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Nonetheless, information on the contribution of specific SSTs on the somatostatin-mediated inhibition
of epileptiform activity is still controversial and apparently species-dependent. In mice, SST2 does
not affect kainate seizure [227], whereas the activation of SST1 plays a role in reducing hippocampal
hyper-excitability [117]. However, additional results have demonstrated the requirement for a critical
SST2 density to regulate hippocampal activity. Indeed, SST2 upregulation as a consequence of
somatostatin gene deletion (SRIF-KO mice) is able to control hippocampal bursting and excitatory
transmission [168]. On the other hand, data on rats seem to exclude the idea that SST1 mediates the
in vivo anticonvulsive effects of somatostatin [100]; rather, SST2 is likely to be involved (e.g., [170,228]).
Knocking out SST4 strongly affects epileptiform activity in the mouse CA1 subfield, although also other
receptors (SST2, SST3) may play roles [106]). Finally, there are indications for functional cooperation
between rat hippocampal SST3/SST4 and SST2 in mediating anticonvulsive effects [229]. As a whole,
these studies suggest that the anticonvulsant action of somatostatin may be mediated by species-specific
receptors. Improving our understanding of how the somatostatin receptor network works, especially
in the human hippocampus, is clearly a pre-requisite for designing new drugs with anti-epileptic
activity [230].
7. Conclusions and Future Perspectives
Somatostatinergic interneurons are key components of the signaling systems inside the retina and
hippocampus, as they fulfill a modulatory role in determining the activity levels of principal neurons.
This is obtained through somatostatin, which regulates single cell excitability and neurotransmission.
By exploiting its capability to work as both a synaptic and paracrine substance, somatostatin can affect
the functioning of the whole neural network, and it helps to shape the firing dynamic range of the
output neurons. In particular, somatostatin sets the cutoff frequency in spiking neurons to avoid
dangerous hyper-excitation. Besides its involvement in regulating network operation, somatostatin
also modulates other biological processes by affecting the functions of non-neuronal cells, such as
glial cells and endothelial cells. Thus, somatostatin contributes to the determination of homeostasis
in neural networks. Since somatostatinergic interneurons are widespread throughout the brain, we
believe that our reasoning on the retina and hippocampus may also apply to other neuronal circuits.
Specifically, somatostatin creates an adequate microenvironment that allows neurons to operate
correctly. In this regard, the transgenic somatostatin-Cre mouse strain, which exhibits a low level of
endogenous somatostatin, may represent a promising model to gain further insights into the role of
somatostatin-based signaling in the regulation of neural network functioning.
Despite several years of investigation, our understanding of the molecular and cellular physiology
of somatostatinergic system in neural networks is far from complete. Somatostatin function has
been addressed through a number of experimental strategies, including pharmacological tools
directed at somatostatin receptors, and transgenic mouse models with knocked-out receptors.
These approaches, however, pose several concerns. Ligand selectivity and the somatostatin receptor
involved may influence the efficiency of coupling to intracellular events, questioning their physiological
relevance. Furthermore, functional cooperation between different receptor subtypes may complicate the
interpretation of the observed effects. Finally, compensatory expression of other receptor subtypes may
occur when knocking out a given somatostatin receptor. In short, molecular mechanisms underlying
receptor–receptor interactions, receptor subtype-selective signaling in target cells, and their impact
on network physiology are only partially understood. This represents a promising avenue for the
development of specific pharmacological SST modulators that are ideal candidates to counteract
neuronal diseases by exerting neuroprotective actions.
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4-AP 4-amino pyridine
AC Adenylyl cyclase
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
BiC Bistratified cell
cAMP Cyclic adenosine monophosphate
CA Cornu ammonis
CaV(L) Voltage-gated L-type calcium channel
CaV(N) Voltage-gated N-type calcium channel
CCK Cholecystokinin
CNS Central nervous system
DA Dopamine
DG Dentate gyrus
EC Entorhinal cortex
EPSC Excitatory post-synaptic current
EPSP Excitatory post-synaptic potential
ERG Electroretinogram
GABA γ-aminobutyric acid
GC Ganglion cell
GCL Ganglion cell layer
GIRK G-protein activated, inwardly rectifying potassium channel
GPCR G-protein coupled receptor
INL Inner nuclear layer
IPL Inner plexiform layer
IPSC Inhibitory post-synaptic current
KCa Voltage-gated and Ca2+-dependent potassium channel
KO Knock-out
KV Voltage-gated potassium channel
LTP Long-term potentiation
M1 ipRGCs Melanopsin-containing, intrinsically photosensitive retinal ganglion cells
NaV Voltage-gated sodium channel
NMDA N-methyl-D-aspartate
NPY Neuropeptide Y
O-LM Oriens lacunosum-moleculare interneuron
ONL Outer nuclear layer
OPL Outer plexiform layer
PKA Protein kinase A
PKC Protein kinase C
PP Perforant pathway
PTX Pertussis toxin
RBC Rod bipolar cell
RP Rod photoreceptor
s.l.m. Stratum lacumosum-moleculare
s.o. Stratum oriens
s.p. Stratum pyramidale
s.r. Stratum radiatum
SRIF Somatotropin release-inhibiting factor
SST Somatostatin receptor
TLE Temporal lobe epilepsy
VIP Vasoactive intestinal peptide
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